Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expressing Solid Tumours”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT05320874
What this trial is testing

KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Who this might be right for
Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd. 232
Early research (Phase 1)UnknownNCT05145179
What this trial is testing

Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Receptor, ErbB-2
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 162
Early research (Phase 1)Looking for participantsNCT07334119
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-Expressing Solid Tumors
Myeloid Therapeutics 60
Early research (Phase 1)Study completedNCT03383692
What this trial is testing

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Who this might be right for
Neoplasm Metastasis
Daiichi Sankyo Co., Ltd. 40
Early research (Phase 1)Looking for participantsNCT06364410
What this trial is testing

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI) 48
Early research (Phase 1)UnknownNCT05819684
What this trial is testing

SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 133
Testing effectiveness (Phase 2)Looking for participantsNCT07228247
What this trial is testing

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Solid Tumors, Adult
Hutchmed 147
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Early research (Phase 1)Ended earlyNCT05013554
What this trial is testing

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Who this might be right for
Neoplasm MalignantBreast CancerLung Neoplasm Malignant+2 more
Sanofi 44
Testing effectiveness (Phase 2)Looking for participantsNCT07646626
What this trial is testing

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD. 150
Early research (Phase 1)UnknownNCT06154343
What this trial is testing

GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd. 150
Early research (Phase 1)UnknownNCT06254807
What this trial is testing

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positive
Carisma Therapeutics Inc 6
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Testing effectiveness (Phase 2)UnknownNCT05349409
What this trial is testing

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Who this might be right for
Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 212
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Testing effectiveness (Phase 2)Study completedNCT02386501
What this trial is testing

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Who this might be right for
HER2 Expressing Solid Tumors
Advaxis, Inc. 12
Next Page